CFTR and cystic fibrosis: Differently from lumacaftor, the first corrector approved for the use of CF patients, that did not influence the fluid reabsorption in HBEC [24], treatment of CF HBEC epithelia with new generation CFTR correctors tezacaftor and elexacaftor and, with the triple combination, TrikaftaTM/KaftrioTM, reduced fluid reabsorption to values closer to those of non-CF-epithelia (Figure 2).